Charles Zhou
Stock Analyst at Guggenheim
(1.50)
# 3,443
Out of 4,983 analysts
11
Total ratings
62.5%
Success rate
-1.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $12.41 | +61.16% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $180.67 | -24.72% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $15.93 | +0.44% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.56 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.14 | +4,812.28% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.77 | +2,498.87% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.36 | - | 2 | Jan 22, 2020 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $12.41
Upside: +61.16%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $180.67
Upside: -24.72%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $15.93
Upside: +0.44%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.56
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.14
Upside: +4,812.28%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.77
Upside: +2,498.87%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.36
Upside: -